The FDA has approved Moderna’s latest COVID-19 vaccine, mNEXSPIKE, for more limited use than its earlier versions.
The new shot is authorized only for adults 65 and older and for people ages 12-64 who have at least one underlying health condition that increases risk for severe illness, according to a May 31 news release from the drugmaker.
Compared to earlier broad authorizations, the narrower scope reflects a more targeted approach as public health officials focus on high-risk populations.
The approval follows the results of a phase 3 clinical trial involving more than 11,000 participants in which results showed the new vaccine had better efficacy than Moderna’s original Spikevax shot.
The company plans to make the vaccine available during the upcoming respiratory virus season, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
